Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy

Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy

The BNT162b2 vaccine against SARS-CoV-2 has a proven efficacy and a favorable safety profile. In cancer patients under immunotherapy in the form of immune-checkpoint inhibitors (ICIs), the efficacy of the vaccine has not been thoroughly studied, while a theoretical concern has also been raised about...

Full description

Bibliographic Details
Main Authors: Panagiotis T. Diamantopoulos, Christina-Nefeli Kontandreopoulou, Aikaterini Gkoufa, Elena Solomou, Amalia Anastasopoulou, Eleni Palli, Panagiotis Kouzis, Spyros Bouros, Mihalis Samarkos, Gkikas Magiorkinis, Helen Gogas
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Cancers
Subjects:
melanoma
immunotherapy
vaccination
immunogenicity
vaccine
Online Access:https://www.mdpi.com/2072-6694/14/15/3791

Internet

https://www.mdpi.com/2072-6694/14/15/3791

Similar Items